Co-Occurrence of Multiple Endocrine Abnormalities Induced by the DIHS/DRESS

Table 2

Cases with more than one endocrinal disorder following DIHS/DRESS from January 2000 to December 2017.

		Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7
Age		15	43	71	47	21	6	17
Gender		F	M	F	F	F	M	F
Causative drugs		Minocycline	Dapsone	Mexiletine	ND	Lamotrigine	Lamotrigine	Zonisamide
Systemic corticosteroid therapy (mg/day) or IVIG		Prednisone therapy at escalating dose from 10 mg once daily to 40 mg twice daily	A tapering dose of prednisone (unknown exact dose of prednisone)	Prednisolone, 60 mg daily	ND	Meprednisone 160 mg (40 mg every 6 hours) followed by 80 mg of prednisone; IVIG	36 mg (1.5 mg/kg/day) of prednisone; IVIG	1 g of meprednisone for 3 days followed by 45 mg of prednisone
Diabetes mellitus	Diagnosis	T1DM	FT1DM	FT1DM	FT1DM	T1DM		T1DM
	Interval of time	7 months	2 months	7 days	ND	ND	4 months	2 months
	Onset by DKA	No	No	ND	Yes	ND	Yes	ND
	HbA1c (%)	8.1%	5.9%	6.0%	6.5%	ND	10.2%	ND
	Fasting C peptide (ng/mL)	ND	ND	<0.05	0.2	ND	ND	ND
	IA-2Ab	Positive	ND	Negative	Negative	Positive	Positive	ND
	ICA-IgG	ND	Negative	Negative	Negative	ND	ND	ND
	GAD	Positive	Negative	Negative	Negative	ND	ND	ND
	IA or IAA	ND	IA is positive	ND	ND	Positive	Positive	ND
Autoimmune thyroid disease	Diagnosis	Graves’ disease	Thyroiditis	HT	Painless thyroiditis	ND	HT	HT
	Interval of time	51 days	2 months	28 days	ND	8 months	4 months	2 months
	Thyroid function test	Primary hyperthyroidism	Remission of thyrotoxicosis within a few weeks	Primary hyperthyroidism	Primary hyperthyroidism	Transient hyperthyroidism and subsequent chronic hypothyroidism	ND	ND
	A-Tg	Positive	ND	Positive	ND	ND	Positive	Positive
	A-TPO	Positive	ND	Positive	ND	Positive	Positive	Positive
	TSI	Positive	Negative	ND	Negative	Positive	ND	Positive
Other involvement of endocrine glands		ND	ND	ND	ND	ND	ND	ND
Country		America	America	Japan	Japan	America	Japan	Japan
Year		2009	2017	2013	2006	2013	2018	2016
Literature

TSI, thyroid-stimulating immunoglobulin.